Possible mechanisms limiting N-methyl-D-aspartate receptor overactivation and the therapeutic efficacy of N-methyl-D-aspartate antagonists - PubMed (original) (raw)
Review
. 1990 Nov;21(11 Suppl):III20-2.
Affiliations
- PMID: 2146778
Review
Possible mechanisms limiting N-methyl-D-aspartate receptor overactivation and the therapeutic efficacy of N-methyl-D-aspartate antagonists
D W Choi. Stroke. 1990 Nov.
Abstract
Cytotoxic overactivation of neuronal N-methyl-D-aspartate receptors is postulated to contribute to the pathogenesis of neuronal loss in hypoxia-ischemia. However, several events associated with hypoxia-ischemia may limit N-methyl-D-aspartate receptor-mediated injury. Perhaps the most important of these events is the development of extracellular acidosis. These limiting events may help explain why N-methyl-D-aspartate receptors contribute to injury more in focal ischemia or hypoxia in vitro than in global ischemia.
Similar articles
- N-methyl-D-aspartate and non-N-methyl-D-aspartate antagonists in global cerebral ischemia.
Diemer NH, Johansen FF, Jørgensen MB. Diemer NH, et al. Stroke. 1990 Nov;21(11 Suppl):III39-42. Stroke. 1990. PMID: 2237983 - Do NMDA antagonists prevent neuronal injury? No.
Buchan AM. Buchan AM. Arch Neurol. 1992 Apr;49(4):420-1. doi: 10.1001/archneur.1992.00530280114032. Arch Neurol. 1992. PMID: 1348413 Review. No abstract available. - Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: a unifying hypothesis.
Siesjö BK, Bengtsson F. Siesjö BK, et al. J Cereb Blood Flow Metab. 1989 Apr;9(2):127-40. doi: 10.1038/jcbfm.1989.20. J Cereb Blood Flow Metab. 1989. PMID: 2537841 Review. No abstract available. - Do NMDA antagonists protect against cerebral ischemia: are clinical trials warranted?
Buchan AM. Buchan AM. Cerebrovasc Brain Metab Rev. 1990 Spring;2(1):1-26. Cerebrovasc Brain Metab Rev. 1990. PMID: 2144995 Review. - Acid tests of N-methyl-D-aspartate receptor gating basics.
Johnson JW. Johnson JW. Mol Pharmacol. 2003 Jun;63(6):1199-201. doi: 10.1124/mol.63.6.1199. Mol Pharmacol. 2003. PMID: 12761326 Review. No abstract available.
Cited by
- Ionotropic glutamate receptors & CNS disorders.
Bowie D. Bowie D. CNS Neurol Disord Drug Targets. 2008 Apr;7(2):129-43. doi: 10.2174/187152708784083821. CNS Neurol Disord Drug Targets. 2008. PMID: 18537642 Free PMC article. Review. - Physiology and pathology of calcium signaling in the brain.
Kawamoto EM, Vivar C, Camandola S. Kawamoto EM, et al. Front Pharmacol. 2012 Apr 13;3:61. doi: 10.3389/fphar.2012.00061. eCollection 2012. Front Pharmacol. 2012. PMID: 22518105 Free PMC article. - Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder.
Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, Wang YS, Wang LJ, Lee IH, Yeh TL, Yang YK, Lu RB, Hong JS. Lee SY, et al. J Psychiatr Res. 2013 Oct;47(10):1343-8. doi: 10.1016/j.jpsychires.2013.06.017. Epub 2013 Jul 18. J Psychiatr Res. 2013. PMID: 23870798 Free PMC article. Clinical Trial. - Amiloride but not memantine reduces neurodegeneration, seizures and myoclonic jerks in rats with cardiac arrest-induced global cerebral hypoxia and reperfusion.
Tai KK, Truong DD. Tai KK, et al. PLoS One. 2013 Apr 8;8(4):e60309. doi: 10.1371/journal.pone.0060309. Print 2013. PLoS One. 2013. PMID: 23593189 Free PMC article. - The cytoprotective effects of dantrolene: a ryanodine receptor antagonist.
Inan S, Wei H. Inan S, et al. Anesth Analg. 2010 Dec;111(6):1400-10. doi: 10.1213/ANE.0b013e3181f7181c. Epub 2010 Sep 22. Anesth Analg. 2010. PMID: 20861418 Free PMC article. Review.